Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan

被引:0
作者
Shetty, SS [1 ]
Delgrande, D [1 ]
机构
[1] Novartis Inst Biomed Res, Summit, NJ 07901 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of valsartan and other nonpeptide angiotensin II type 1 (AT(1)) receptor blockers on the prejunctional actions of angiotensin II were investigated in the isolated left atria of rat. Norepinephrine stores in rat atria were loaded with [H-3] norepinephrine, and neuronal norepinephrine release was deduced from the radioactivity efflux. Angiotensin II (10(-9) to 10(-6) M) produced concentration-dependent enhancement of the electrical stimulation-induced efflux of [H-3] norepinephrine from the preparation. Pretreatment of tissues with valsartan, irbesartan, eprosartan, or losartan (10(-8) to 10(-6) M) produced concentration- dependent inhibitions of the stimulation-induced efflux of radioactivity observed in the presence of angiotensin II (10(-7) M). The AT(1) receptor blockers did not decrease the "basal" stimulation-induced overflow of radioactivity but rather selectively inhibited the angiotensin II-mediated augmentation of the response. Regression analyses of the inhibition of the angiotensin II-mediated response by valsartan, irbesartan, eprosartan, and losartan revealed corresponding log IC50 values (log M, with 95% confidence intervals) of -7.78 (-8.19, -7.51), -7.65 (-8.02, -7.40), -7.12 (-7.37, -6.86), and -6.75 (-7.00, -6.40), indicating that the IC50 values for valsartan and irbesartan are significantly lower than those for eprosartan and losartan. Thus, valsartan is a potent inhibitor of the prejunctional facilitatory effect of angiotensin II on the release of norepinephrine from peripheral sympathetic nerves. This implies that the therapeutic domain of valsartan may be extended to include pathophysiological conditions such as congestive heart failure wherein prejunctional angiotensin II receptors apparently play a significant role. Whether the high potency of valsartan translates into a significant clinical advantage relative to the other agents tested remains to be ascertained.
引用
收藏
页码:179 / 186
页数:8
相关论文
共 40 条
  • [21] Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
    Marino, MR
    Langenbacher, KM
    Raymond, RH
    Ford, NF
    Lasseter, KC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (04) : 347 - 356
  • [22] Pharmacokinetics and protein finding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment
    Martin, DE
    Chapelsky, MC
    Ilson, B
    Tenero, D
    Boike, SC
    Zariffa, N
    Jorkasky, DK
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (02) : 129 - 137
  • [23] LOCALIZATION AND PROPERTIES OF ANGIOTENSIN RECEPTORS
    MENDELSOHN, FAO
    [J]. JOURNAL OF HYPERTENSION, 1985, 3 (04) : 307 - 316
  • [24] EVIDENCE OF A SELECTIVE INCREASE IN CARDIAC SYMPATHETIC ACTIVITY IN PATIENTS WITH SUSTAINED VENTRICULAR ARRHYTHMIAS
    MEREDITH, IT
    BROUGHTON, A
    JENNINGS, GL
    ESLER, MD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (09) : 618 - 624
  • [25] The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects
    Morgan, JM
    Palmisano, M
    Piraino, A
    Hirschhorn, W
    Spencer, S
    Prasad, PP
    Ortiz, M
    Lloyd, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (01) : 35 - 44
  • [26] Munch G, 1996, BRIT J PHARMACOL, V118, P1855
  • [28] Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
    Ohlstein, EH
    Brooks, DP
    Feuerstein, GZ
    Ruffolo, RR
    [J]. PHARMACOLOGY, 1997, 55 (05) : 244 - 251
  • [29] PHARMACOKINETICS AND BIOCHEMICAL EFFICACY AFTER SINGLE AND MULTIPLE ORAL-ADMINISTRATION OF LOSARTAN, AN ORALLY ACTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, IN HUMANS
    OHTAWA, M
    TAKAYAMA, F
    SAITOH, K
    YOSHINAGA, T
    NAKASHIMA, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (03) : 290 - 297
  • [30] RAND MJ, 1990, CARDIOVASCULAR PHARM, P229